Contraindication added to Janssen COVID-19 vaccine; Pfizer announce final results for their COVID-19 oral antiviral; A new treatment for benign prostatic hyperplasia; REMS change for CAR T-cell therapy, and Rinvoq gains approval for active psoriatic arthritis.
Entadfi is a fixed-dose combination of finasteride, a 5α-reductase inhibitor, and tadalafil, a phosphodiesterase 5 (PDE5) inhibitor.
Men who take 5-alpha-reductase inhibitors while on active surveillance for prostate cancer are less likely to experience cancer progression, according to a new study
It is important for urologists and primary care physicians to be aware of the potential link between BPH medications and heart failure risk, according to investigators.
Use of glycolysis-enhancing drugs terazosin, doxazosin, or alfuzosin tied to lower risk for developing Parkinson disease than use of tamsulosin
In a small study, add-on vibegron appeared well-tolerated and clinically effective among men with persistent OAB.
Younger patients and those with alopecia have significant disproportionality signals for increased suicidality
Increased risk seen among men using dutasteride, finasteride for benign prostatic hyperplasia
Finasteride is not associated with an increased risk for death due to prostate cancer, according to a research letter published in the New England Journal of Medicine.
While bethanechol, a cholinergic agonist, may “theoretically” improve detrusor contractility in women with underactive bladder (UAB), the evidence supporting its use is limited.
